Shanghai Allist Pharmaceuticals Hits Day High with 4% Intraday Surge

Shanghai Allist Pharmaceuticals Co., Ltd. has experienced a notable uptick today, gaining 4.0% as of March 24, 2026. The stock reached an intraday high of CNY 91.83, reflecting strong performance against the backdrop of the China Shanghai Composite, which rose by 1.78% on the same day. In terms of performance metrics, Shanghai Allist has shown resilience over the past year, with a return of 17.79%, outpacing the China Shanghai Composite's 15.17%. However, year-to-date performance indicates a decline of 12.13%, contrasting with the broader index's decrease of 2.21%. Over a three-year horizon, the stock has surged by an impressive 271.28%, significantly outperforming the composite's 18.85% growth. The company has consistently reported positive results for the last ten consecutive quarters, with a robust operating cash flow of CNY 2,163.79 million and a net profit growth of 59.72% to CNY 1,187.76 million. With a return on equity of 29.94% and a price-to-book ratio of 6.63, Shanghai Allist Pharmaceuticals maintains a strong market position within the pharmaceuticals and biotechnology sector.